Page 2 - Orbit Discovery News Today

Start-up SanegeneBio Inc, focused on developing novel RNAi-based medicines has entered into a Master Service Agreement with Orbit Discovery (Oxford UK), a leader in the discovery of therapeutic peptide hits. Click to read more...

Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a Master Service Agreement with SanegeneBio Inc., (Sanegene), a start-up company

Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a Master Service Agreement with SanegeneBio Inc.

Biopharmaceutical company Orbit Discovery has been awarded a £472,000 Smart grant by Innovate UK, to facilitate the implementation of droplet-based microfluidics for cell-based functional screening to advance the discovery of peptide therapeutic candidates. Click to read more...

Peptide technology company Orbit Discovery has announced a partnership with WuXi AppTec that will see the combination of its peptide discovery platform and experience with the Chinese organisation’s downstream capabilities as a leading global provider of R&D and manufacturing services provision for the pharmaceutical and healthcare industry. Click to read more...

WuXi AppTec’s development and manufacturing platform will enable Orbit to generate peptides at small or large scale

Orbit Discovery Raises $7.6M in Funding Orbit Discovery, an Oxford, England, UK-based biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, raised $7.6m (USD) in funding. The financing was led by Oxford Sciences Innovation, with participation from Borealis Ventures, Perivoli Innovations, and other institutional and individual investors, including Kapil Dev Joory. Proceeds from the financing...

Published: Jul 02, 2021 By Alex Keown OcuTerra Therapeutics – David J. Tanzer was named Chief Medical Officer and Executive Vice President, Clinical and Medical Affairs for Boston-based OcuTerra. Prior to joining OcuTerra, Tanzer served as Global Executive Medical Director in the Novartis ophthalmology franchise. Before that, he served as the CMO at Abbott Medical Optics. He also led the Navy Refractive Surgery Program in San Diego, participating as principal or co-investigator in ove...